Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.61 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.52 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30033876 | 1.00 | ADORA3 (0.61) | ADORA3ENPP1P2RY1HIF1APOLB | |
| SCHEMBL29450534 | 0.86 | POLB (0.66) | ENPP1P2RY1HIF1APOLB | |
| SCHEMBL30229633 | 0.86 | POLB (0.54) | ENPP1P2RY1HIF1APOLB | |
| SCHEMBL2986957 | 0.86 | POLB (0.66) | ENPP1P2RY1HIF1APOLB | |
| SCHEMBL1401255 | 0.86 | POLB (0.54) | ENPP1P2RY1HIF1APOLB | |
| SCHEMBL31685679 | 0.85 | ADORA3 (0.62) | ADORA3ENPP1P2RY1POLB | |
| SCHEMBL28912656 | 0.85 | ADORA3 (0.69) | ADORA3HIF1ASLC29A1 | |
| SCHEMBL23982373 | 0.84 | HIF1A (0.71) | ADORA3HIF1ASLC29A1 | |
| SCHEMBL548569 | 0.84 | HIF1A (0.71) | ADORA3HIF1ASLC29A1 | |
| SCHEMBL6267085 | 0.84 | HIF1A (0.71) | ADORA3HIF1ASLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113549941-B | Microelectrode array and method for electrochemical synthesis of compound by using same | 东南大学 | 2022-08-26 | — | — | CN | disclosed |
| CN-113549941-A | Microelectrode array and method for electrochemical synthesis of compound by using same | 东南大学 | 2021-10-26 | — | — | CN | disclosed |
| US-20050227933-A1 | Treatment of bacterial induced diseases using DNA methyl transferase inhibitors | BENKOVIC STEPHEN J | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227933-A1 | Treatment of bacterial induced diseases using DNA methyl transferase inhibitors | DNMT1, TPMT, GNMT | ADORA3 4134/4885ENPP1 254/4885P2RY1 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.